Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sertraline - Pfizer

Drug Profile

Sertraline - Pfizer

Alternative Names: Aremis; Besitran; CP 51974; CP 51974 01; Gladem; J Zoloft; Lustral; Serad; Serlain; Tatig; Zoloft

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Amines; Antidepressants; Anxiolytics; Naphthalenes; Small molecules
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder; Obsessive-compulsive disorders; Panic disorder; Post-traumatic stress disorders; Premenstrual dysphoric disorder; Social phobia
  • No development reported Generalised anxiety disorder
  • Discontinued Night eating syndrome; Premature ejaculation

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Sep 2016 Pfizer completes a phase I trial in Healthy volunteers in Belgium (NCT02651623)
  • 01 Jan 2016 Pfizer initiates enrolment in a phase I trial in Healthy volunteers in Belgium (NCT02651623)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top